QNTA - QNTA STOCK NEWS

Medolife Rx, a bioceutical company and a subsidiary of Quanta (OTC PINK: QNTA), announced positive pre-clinical study results for its lead drug candidate Escozine®. The study revealed that Escozine® enhances the efficacy of standard chemotherapy agents like Cyclophosphamide, Etoposide, and Cisplatin in inducing apoptosis in leukemia and lymphoma cell lines. Conducted at a leading cancer research institution, the study demonstrated a synergistic effect, indicating Escozine® could significantly improve cancer treatment outcomes. The company plans to advance Escozine® into human trials in the U.S. and Dominican Republic.

Quanta, Inc. (QNTA) announced its annual financial results for 2020, noting over $1 million in revenue attributed to its subsidiary, Medolife Rx. New CEO Dr. Arthur Mikaelian highlighted the company's stability during the pandemic and ongoing efforts to reduce liabilities. Medolife is advancing its lead drug candidate Escozine®, pursuing FDA approval and product registration in the Dominican Republic. The company is also expanding its manufacturing capabilities and has received a significant order for its nutraceutical product, Immunapen.

Medolife Rx, a bioceutical company, announced that Quanta's President, Philip Sands, will present at the 2021 Sequire Cannabis Conference on April 20. Sands will discuss the future development of Medolife and Quanta in the bioceutical sector, emphasizing technology, pharmaceutical research, and consumer wellness products in the CBD market. The conference aims to connect investors with industry leaders. Medolife Rx's clinical programs include Escozine®, a treatment derived from scorpions, being researched for COVID-19 and cancer, highlighting their innovative approach to pharmaceuticals.

Medolife, a subsidiary of Quanta (OTC PINK: QNTA), announced the final data submission to the FDA for its lead drug candidate, Escozine®, aimed at treating COVID-19. The submission includes detailed manufacturing information and safety data from a human study with over 500 participants. The company expects the FDA to grant IND designation, facilitating U.S. distribution of Escozine®. This approval could also enhance interest in further clinical applications, including potential cancer therapies. CEO Dr. Arthur Mikaelian emphasizes the importance of FDA approval for global research expansion.

Medolife Rx, a subsidiary of Quanta (QNTA), announced promising pre-clinical results for its drug candidate Escozine®, achieving up to 95% Specific Induced Apoptosis (SIA) in leukemia cells during studies conducted at a leading US cancer research center. The study tested Escozine® on various cancer cell lines and in Chronic Lymphocytic Leukemia patients, consistently showing significant cell death at high concentrations. CEO Dr. Arthur Mikaelian emphasized the groundbreaking nature of these results and their potential impact on cancer treatment worldwide.

Medolife Rx, a global bioceutical company and subsidiary of Quanta (QNTA), announced a significant purchase order for 1,400 units of its nutraceutical product Immunapen™ from a pharmaceutical wholesaler in Armenia. The product, designed to enhance immune function, leverages a proprietary formulation derived from scorpion peptides. This order marks the beginning of a potential long-term partnership, as the company anticipates a rise in demand for immune-boosting products during the ongoing COVID-19 pandemic, a sector projected to grow to $25 billion by 2025.

Medolife Rx, a subsidiary of Quanta, Inc. (OTC PINK: QNTA), has received a formal recommendation from Dr. Ramón Feliz, MD, PhD, for its drug candidate Escozine® as part of cancer treatment regimens. Dr. Feliz observed significant benefits in patients using Escozine®, including improvements in quality of life, pain reduction, and tumor mass decrease. Medolife is conducting further clinical studies in the U.S. and Dominican Republic. The company is also seeking FDA approval for Escozine® for various applications, including treatment for COVID-19.

Medolife Rx, a subsidiary of Quanta (OTC PINK: QNTA), has expanded its scorpion reservation in the Dominican Republic by 6,350 sq. meters, enhancing the cultivation of peptides for its lead drug candidate, Escozine®. This drug targets SARS-CoV-2 and is awaiting registration. The region's ideal climate supports scorpion populations, with an estimated demand for Escozine® reaching one million doses post-registration. Additionally, the company plans to establish a lab to reduce production costs and integrate its supply chain, while leveraging the high value of scorpion-derived peptides.

Medolife Rx, a subsidiary of Quanta (OTC PINK: QNTA), announced successful clinical trial results for its lead drug candidate, Escozine®. The drug completely eradicated in vitro cancer cell lines for bladder and ovarian cancers during a 24-hour study, conducted at a prestigious U.S. research facility. The study confirmed the drug's efficacy, particularly with its polarization technology, which enhances drug potency. Medolife is concurrently pursuing product registration for Escozine® as a COVID-19 therapeutic in the Dominican Republic, aiming for broader clinical applications.